Merck Serono has taken steps to expand its franchise in multiple sclerosis by acquiring exclusive rights to an experimental drug described as a second-generation peptide copolymer. Teva Pharmaceuticals’ Copaxone is also a peptide copolymer. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
